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Perfluorooctanoic  acid (PFOA)  is  used  in the manufacture  of  many  industrial  and  commer-
cial products.  PFOA  does  not  readily  decompose  in  the  environment,  and  is biologically
persistent.  Human  epidemiologic  and  animal  studies  suggest  that PFOA  exposure  elicits
adverse effects  on  the  pancreas.  While  multiple  animal  studies  have  examined  PFOA-
mediated  toxicity  in the liver,  little  is  known  about  the  potential  adverse  effects  of PFOA
on  the pancreas.  To  address  this,  we treated  C57Bl/6  mice  with  vehicle,  or PFOA  at doses
of 0.5,  2.5  or  5.0  mg/kg  BW/day  for 7 days.  Significant  accumulation  of  PFOA  was  found  in
the serum,  liver  and  pancreas  of  PFOA-treated  animals.  Histopathologic  examination  of  the
pancreas revealed  focal  ductal  hyperplasia  in  mice  treated  with  2.5 and  5.0  mg/kg  BW/day
PFOA, while  inflammation  was  observed  only  in  the  high  dose  group.  Elevated  serum  lev-
els of amylase  and lipase  were  observed  in  the  2.5 mg/kg  BW/day  PFOA  treatment  group.
In addition,  PFOA  exposure  resulted  in  a dose-dependent  increase  in the  level  of the lipid
peroxidation  product  8-iso-PGF2 and  induction  of the  antioxidant  response  genes  Sod1,
Sod2,  Gpx2  and  Nqo1.  Our  findings  provide  additional  evidence  that  the  pancreas  is a target
organ for  PFOA-mediated  toxicity  and  suggest  that  oxidative  stress  may  be a mechanism
through  which  PFOA  induces  histopathological  changes  in  the  pancreas.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Perfluoroalkyl and polyfluoroalkyl substances (PFASs),
uch as perfluorooctanoic acid (PFOA), are widely used in
onsumer  and industrial applications due to their unique
ydrophobic properties. PFASs do not readily decompose
n  the environment and have been detected in air, soil, sur-
ace  water, sediments, ice caps and wildlife worldwide [1].
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icenses/by-nc-nd/3.0/).Humans are exposed to PFOA by drinking water, dust in
homes,  food products or migration from food packaging
and cookware [1,2]. Detectable levels of PFOA are found in
98%  of the American population, with mean serum levels
measured at 3.9 ng/ml [3]. PFOA is readily absorbed, but
poorly  eliminated with a predicted half-life of 3.8 years in
humans.
Based  on its biological persistence, it has been postu-
lated that exposure to PFOA has the potential to contribute
to  development of chronic diseases in humans. Epidemi-
ologic studies have shown an association between PFAS
exposure and adverse health effects in humans [1,4].
Studies of occupationally-exposed workers, community
residents exposed to contaminated drinking water, as well
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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as general population studies have identified a positive
association between PFOA exposure and increased total
serum  cholesterol and non-HDL cholesterol [5–7]. A gen-
eral  population study revealed an increase in obesity, as
well  as serum insulin and leptin levels in 20-year-old
female offspring exposed to PFOA in utero [8]. PFOA was
also  associated with increased mortality due to diabetes in
an  occupationally-exposed cohort [9]. In addition, a weak
association was seen between PFOA levels and pancreatic
cancer in a general population study [10].
In rodents, exposure to PFOA results in reduced
body weight, liver enlargement, decreased triglycerides,
and hepatic peroxisomal proliferation [1,11]. The hepatic
effects  of PFOA have been attributed in large part to
activation of the nuclear receptor peroxisome proliferator-
activated receptor alpha (PPAR), although PPAR-
independent effects have also been reported [12]. More
recent  studies have shown that PFOA disrupts the
endocrine and immune systems and exerts multiple devel-
opmental effects in mice [13–15]. Female mice exposed
to  low levels of PFOA in utero displayed elevated serum
leptin and insulin levels and increased body weight [14].
Chronic exposure to PFOA has been shown to induce a
“tumor  triad” in Sprague-Dawley rats, consisting of liver,
Leydig  cell and pancreatic acinar cell tumors (PACTs) [16].
While  liver tumor formation is proposed to be mediated
predominantly through PPAR activation [17], the mecha-
nism  by which PFOA induces PACTs is not well understood
[16]. Due to the fact that pancreatic ductal adenocarcinoma
(PDAC) exhibits a ductal morphology, it was previously
thought that PDAC arises from ductal epithelial cells [18].
However, more recent studies have shown that targeting
expression of oncogenic KRas to adult mouse acinar cells
leads  to development of PDAC, firmly establishing the aci-
nar  cell as a cell of origin for pancreatic cancer [19–21].
Oxidative stress occurs when reactive oxygen species
(ROS) production exceeds the capacity of the cells’ detoxi-
fication mechanisms [22]. ROS can cause lipid, protein, and
DNA  damage and contribute to the pathology observed
in  several chronic diseases including cancer [22]. Previ-
ous  experimental evidence exists demonstrating that PFOA
induces  oxidative stress. PFOA has been shown to stimulate
ROS  production in HepG2 cells [23–25] which led to oxida-
tive  DNA damage, assessed by the immunocytochemical
detection of 8-hydroxydeoxyguanosine (8OHdG) [25], and
activation  of caspase-9 and apoptosis [24].
While the effects of PFOA in the liver have been exten-
sively studied, few studies have evaluated the effects of
PFOA  on the pancreas. The goal of this study was  to charac-
terize  the adverse effects of short-term exposure to PFOA
in  the pancreas.
2.  Materials and methods
2.1.  Chemicals
PFOA (96%), ammonium acetate, potassium hydroxide
and ethyl acetate were purchased from Sigma–Aldrich (St.
Louis,  MO). Perchloric acid was purchased from ACROS
(Fair  Lawn, NJ). 8-iso-PGF2 and 8-iso-PGF2-d4 were pur-
chased from Cayman Chemical (Ann Arbor, MI). n-HexaneReports 1 (2014) 513–521
was  obtained from Baker Chemicals (Houston, TX). Water,
acetone, methanol and acetonitrile were LC–MS grade and
purchased from Fisher Scientific (Pittsburgh, PA).
2.2.  Study design
Eight-week-old male C57Bl/6 mice were purchased
from Harlan Laboratories (Indianapolis, IN), and were
acclimated for 4 days prior to treatment. Mice were
singly housed in polycarbonate cages with filter tops, and
received  LabDiet 5015 in pelletized form and de-ionized
water ad libitum. The care and treatment of the mice were
in  accordance with the NIH Guide for the Care and Use of
Laboratory Animals and was approved by the Indiana Uni-
versity  Bloomington IACUC. Due to lack of gender-specific
differences in elimination of PFOA [26], mice have been
extensively used to evaluate the adverse effects of PFOA
exposure [27]. Groups of 4 mice were treated with water
(control) or PFOA (0.5, 2.5 or 5.0 mg/kg BW)  via oral gav-
age  (1×/day at a volume of 0.1 ml/10 g BW)  for 7 days.
These doses have previously been used in mouse studies
evaluating the effects of PFOA [14]. An additional group
of  mice were treated with cerulein for 7 days (1×/day,
5 g, i.p.) to stimulate pancreatitis. Mice were killed by CO2
asphyxiation, and serum, pancreata and livers collected
24  h after the last treatment. Pancreata were divided in
half  along the longitudinal axis, from the head to tail of
the  pancreas. The top section was used for histology for all
pancreata. Pancreas and liver sections were fixed in forma-
lin  for 48 h and then embedded in paraffin, sectioned and
stained  with H&E for histopathologic examination. Images
were  captured with an Aperio whole slide imaging system
at  20× magnification. The remaining pancreata and liver
were  snap frozen in liquid nitrogen for further biochem-
ical and gene expression analysis. For the quantitation of
PFOA  and 8-iso-PGF2 in pancreas and liver, frozen tissues
were  homogenized in buffer containing 20 mM Tris buffer,
20  M BHT at pH 7.4 on ice. Supernatants were collected
following centrifugation at 16,000 × g for 5 min, and stored
at  −80 ◦C until use.
2.3.  PFOA quantitation
One  ml  acetonitrile was added to serum or tissue
homogenates, vortexed for 15 s and sonicated for 5 min.
Samples were centrifuged at 16,000 × g for 3 min. An equal
volume of supernatant was  then mixed 1:1 with LC–MS
grade water containing 3 mM ammonium acetate. PFOA
was  quantified using an Agilent 1260 UPLC system coupled
with  an Agilent 6430 triple quadrupole mass spectrom-
eter. The samples were separated on an Agilent Zorbax
Eclipse XBD-C18 column at 30 ◦C. Analytes were eluted in
water  containing 3 mM ammonium acetate and acetoni-
trile  (50:50, v/v) at a flow-rate of 0.3 ml/min. The separated
PFOA was detected by mass spectrometry with an elec-
trospray ion source operating in the negative ion mode
(ESI−) using MRM.  Precursor ion (m/z 413) and product
ions (m/z 369 and m/z 169) were monitored at a frag-
mentation voltage of 66, cell acceleration voltage of 4, and
collision  energy of 1 and 13 for each product ion. PFOA lev-
els  were quantified from a standard curve prepared at final
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oncentrations between 0 and 50 pg/l using Agilent Mass
unter  (v B.04.00) software.
.4.  Amylase and lipase measurements
Amylase and lipase activities in serum were measured
pectrophotometrically, using kits from Pointe Scientific
nc.  (Canton, MI)  according to the manufacturers’ instruc-
ions.
.5.  Measurement of 8-iso-PGF2˛
Samples were prepared as described with modifica-
ions [28]. Briefly, standards or tissues were spiked with
 ng of the internal standard, 8-iso-PGF2-d4. 15% KOH
1:1,  v/v) was added, vortexed, then hydrolyzed at 40 ◦C
or  30 min. Formic acid (1.2 M final concentration) was
dded,  then centrifuged at 16,000 × g for 3 min. Super-
atants were transferred into glass tubes and extracted
ith ethyl acetate/hexane (3:1, 3× volume) twice at room
emperature. The combined organic phases were evapo-
ated  under nitrogen and reconstituted in 80 l mobile
hase.
8-iso-PGF2 and 8-iso-PGF2-d4 were quantified using
n  Agilent 1260 UPLC system coupled to an Agilent 6430
ass  spectrometer. The analytes were separated by gra-
ient  elution (flow fate of 0.35 ml/min) on an Agilent
oroshell 120 SB-C18 column (4.6 mm × 100 mm 2.7-m),
t  45 ◦C. Mobile phase A consisted of LC–MS grade water
ontaining 0.01% of acetic acid; mobile phase B contained
ethanol and acetonitrile (50:50, with 0.01% of acetic acid).
he  column was first equilibrated to 65% B; following sam-
le  injection (20 l) the solvent mix  was increased to 77% B
ver  6 min, held at 77% B for 2 min, increased to 95% B over
.5  min, then the column was reequilibrated to 65% B for
.5  min. The UPLC system was coupled to an electrospray
on source operated in negative ion mode (ESI−). Voltages
or  the fragmentor, collision energy, and cell accelerator
ere set at 135, 27, and 4, respectively. The ESI source tem-
erature  was set at 350 ◦C, with a gas flow of 10 L/min and a
ebulizer  pressure of 50 psi. 8-iso-PGF2 and 8-iso-PGF2-
4  were detected using multiple reaction monitoring for
he  following transitions: 8-iso-PGF2, m/z 353.3 to 193.2,
nd  m/z 353.3 to 247.3; 8-iso-PGF2-d4, m/z 357.3 to 197.0,
nd  m/z 357.3 to 251.3. An 8-iso-PGF2 standard curve was
onstructed at concentrations between 0 and 200 pg/ml.
-iso-PGF2 was quantified from the response ratio of 8-
so-PGF2:8-iso-PGF2-d4 using Agilent Mass Hunter (v
.04.00) software.
.6.  Quantitative RT-PCR analysis
Total RNA was prepared from pancreas and liver using
rizol (Invitrogen). 5.0 g of total RNA was reverse-
ranscribed (RT) with Superscript II reverse transcriptase
Invitrogen) using random hexamers (Roche) for priming.
eal-time PCR was performed using FastStart Universal
YBR Green Master Mix  (Roche) and gene-specific primers
n  an Illumina Eco Real-time PCR System. Primer pairs
or  specific genes were designed using the Primer Express
rogram (Applied Biosystems), with -actin amplificationReports 1 (2014) 513–521 515
used as the endogenous control. Primer sequences are
listed  in Supplemental Data, Table 1. Samples were mea-
sured  in triplicate and analyzed by the threshold cycle (Ct)
comparative method. The 2−Ct value was calculated,
where Ct = Cttarget − Ct-actin and Ct  = Ctsample −
Ctreference. Relative quantitation for each gene is shown,
where control levels in the pancreas were set to 1.0.
Supplementary Table 1 related to this article can
be found, in the online version, at doi:10.1016/j.toxrep.
2014.07.015.
2.7. Statistical analysis
The  data were analyzed by one-way ANOVA followed by
a  Dunnett’s two-tailed test for comparison against controls
when  the overall model indicated a statistically significant
effect. For all studies, treatment groups were considered
significantly different from control values when p < 0.05.
3. Results
3.1. Effect of PFOA on organ weight, tissue histology and
pancreatic enzymes
We  hypothesized that treatment of C57Bl/6 mice with
PFOA  would lead to PFOA accumulation in the pancreas
resulting in pancreatic damage. To address this, we  con-
ducted  a 7 day exposure study in male C57Bl/6 mice.
Water or PFOA dissolved in water was  administered by
gavage  at doses of 0.5, 2.5, and 5.0 mg/kg BW/day for 7
days.  Our design also included a cerulein treatment group
(5  g/day, i.p.) which elicits a mild form of chronic pan-
creatitis in rodents [29]. In this way, we could compare
results obtained with an agent that induces oxidative stress
selectively in the pancreas, i.e. cerulein, compared to PFOA,
which  produces effects in several tissues including the
liver.  Mice were sacrificed 24 h after the last treatment and
absolute  and relative pancreatic and liver weights were
determined. Body weights were not different between
controls and treatment groups (Table 1). However, PFOA
caused  a significant dose-related increase in absolute and
relative  liver weight, consistent with previous studies in
rodents  which demonstrate hepatomegaly following PFOA
exposure  [17]. PFOA significantly decreased the absolute
pancreas weight in the 5.0 mg/kg BW/day treatment group;
however, the relative pancreas weight was not significantly
different from controls (Table 1).
Previously, levels of PFOA have been commonly mea-
sured in the liver, kidney and serum of rodents following
PFOA treatment [11,27]; however quantitative measure-
ments of PFOA in the pancreas have not been evaluated.
In the present study, measurement of PFOA levels by
LC–MS/MS demonstrates that the concentration of PFOA
increases in a dose-dependent manner in the liver and
serum following 7 days of treatment (Table 2). In addition,
PFOA also exhibited a dose-dependent linear accumulation
in  the pancreas in all PFOA treatment groups (Table 2).Histologic changes elicited by PFOA treatment were
evaluated in H&E stained pancreatic sections (Fig. 1). As
shown  in Fig. 1B, PFOA exposure of 5.0 mg/kg BW/day led to
the  appearance of focal ductal hyperplasia (white arrows).
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Table  1
Body,  pancreas and liver weights of C57Bl/6 mice treated with PFOA for 7 days.a
Final body weight (g) Pancreas weight (g) Relative pancreas weight (%)b Liver weight (g) Relative liver weight (%)b
Control 25.9 ± 0.6 0.122 ± 0.011 0.47 ± 0.05 1.30 ± 0.03 5.02 ± 0.05
PFOA  0.5 mg/kg 25.9 ± 1.6 0.126 ± 0.017 0.49 ± 0.04 1.45 ± 0.11* 5.62 ± 0.14*
PFOA 2.5 mg/kg 26.4 ± 0.7 0.138 ± 0.008 0.52 ± 0.02 2.08 ± 0.06* 7.87 ± 0.08*
PFOA 5.0 mg/kg 24.9  ± 0.1 0.104 ± 0.008* 0.42 ± 0.03 2.30 ± 0.02* 9.24 ± 0.06*
Cerulein 25.0 ± 1.2 0.116 ± 0.002 0.46 ± 0.10 1.31 ± 0.05 5.26 ± 0.11*
a Data represent the mean ± S.D. in = 4 mice/group.
b Relative organ weight = (organ weight/body weight) × 100.
* Significantly different from control (p < 0.05).
Table 2
PFOA  levels in pancreas, liver and serum.a
Pancreas (ng/mg tissue) Liver (ng/mg tissue) Serum (ng/ml)
Control 0.09 ± 0.02 0.10 ± 0.03 5.5 ± 1.9
PFOA  0.5 mg/kg 0.32 ± 0.07* 5.90 ± 0.52* 4162.6 ± 399.9*
PFOA 2.5 mg/kg 1.57 ± 0.13* 53.54 ± 5.27* 28,878.3 ± 2871.7*
PFOA 5.0 mg/kg 3.33 ± 0.87* 103.07 ± 2.10* 47,984.2 ± 4427.4*
Cerulein 0.17 ± 0.08 
a Data represent the mean ± S.D. in = 4 mice/group.
* Significantly different from control (p < 0.05).
Focal ductal hyperplasia was observed in all mice in the
high  dose group (4/4) while 50% of mice (2/4) of the
2.5 mg/kg BW/day group displayed similar changes. The
pancreata of mice in the control and 0.5 mg/kg BW/day
treatment groups did not display these changes. Con-
sistent with previous reports [30], we observed that
cerulein treatment led to widespread areas of acinar-to-
ductal metaplasia (ADM) (Fig. 1C). PFOA at a dose of
5.0  mg/kg BW/day, as well as cerulein treatment, increased
the  number of white blood cells in the vessel lumens,
indicative of inflammation (Fig. 1E and F), as compared to
the  control pancreas (Fig. 1D). Serum amylase and lipase
measurements were determined to assess the effect of 7
day  exposure to PFOA on the pancreas. As shown in Fig. 2,
serum  amylase and lipase levels were significantly ele-
vated  in the 2.5 mg/kg PFOA exposure group (32% and 52%
increases, respectively).
Fig. 1. PFOA treatment for 7 days leads to histopathologic changes in the pancre
captured  with an Aperio whole slide imaging system (20× magnification) are s
cerulein  (C, F) treatment groups. Depicted are examples of normal ductal morph
metaplasia, white arrows (C). The presence of inflammatory cells in the lumen of0.12 ± 0.04 9.5 ± 5.0
3.2.  Effects of PFOA on oxidative lipid damage
We next determined whether PFOA exposure resulted
in  oxidative damage to the pancreas and liver, as assessed
by  quantifying the lipid peroxidation product 8-iso-PGF2,
also  known as F2-8-isoprostane. As shown in Fig. 3A, PFOA
administration led to a dose-dependent increase in 8-iso-
PGF2 levels in the pancreas, with 2.3-fold higher levels
observed in the high dose group, as compared to con-
trols. Cerulein administration, which causes a mild form
of  pancreatitis, also led to a significant (2.6-fold) increase
in  8-iso-PGF2 levels in the pancreas. In contrast, PFOA at
the  highest dose produced only a 1.5-fold increase in 8-iso-
PGF2 levels in the liver (Fig. 3B). The level of 8-iso-PGF2
was  not significantly increased by cerulein in the liver.
When comparing the levels of 8-iso-PGF2 between the
liver  and the pancreas, the fold-changes were significantly
as. Representative H&E stained pancreas sections obtained from images
hown from control (A, D), 5.0 mg/kg BW/day PFOA treatment (B, E) and
ology (A), focal ductal hyperplasia, white arrow (B) and acinar-to-ductal
 blood vessels is denoted by the black arrows (D–F). Scale bars: 100 M.
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Fig. 3. PFOA treatment leads to increased lipid peroxidation in the pan-
creas of mice treated with PFOA for 7 days. 8-iso-PGF2 was quantified as
a  measure of lipid peroxidation in the pancreas (A) and liver (B) of mice
(n = 4/group) treated with PFOA or cerulein for 7 days using LC–MS/MS as
detailed in Section 2. Data are expressed as mean ± S.D. *Significantly dif-
ferent from control (p < 0.05). #Significant difference between fold changen  = 4/group) treated with PFOA or cerulein for 7 days. Levels were deter-
ined 24 h after the last administration. Data are presented as mean ± S.D.
Significantly different from control (p < 0.05).
igher in the pancreas when compared to the liver at all
oses  of PFOA (Fig. 3).
.3.  PFOA-mediated induction of antioxidant genes in the
ancreas and liver
Induction  of antioxidant genes commonly occurs as a
esponse to oxidative stress. As PFOA has been shown
o  increase the activities of superoxide dismutase (Sod)
nd  catalase (Cat) in HepG2 cells and cultured tilapia
epatocytes [31,32], we  next determined whether gene
nduction occurs in vivo in the pancreas or the liver as
 result of PFOA treatment. Although basal mRNA lev-
ls  of the cytosolic form of Sod, Sod1, are 4-fold higher
n  the pancreas as compared to the liver, PFOA treat-
ent led to a similar (2-fold) induction of mRNA levels
n  both the pancreas and the liver (Fig. 4A). PFOA treat-
ent also increased mRNA levels of the mitochondrial form
f  Sod, Sod2, by approximately 3-fold in the liver and 2-
old  in the pancreas (Fig. 4B). We  observed that mRNA
evels of glutathione peroxidase 1 (Gpx1) did not change
ith  PFOA treatment in either the liver or pancreas (datain  the pancreas as compared to the liver (p < 0.05).
not shown); however, Gpx2 levels increased 1.5-fold in
the  pancreas in the 2.5 and 5.0 mg/kg BW/day PFOA treat-
ment  groups, while these levels were not altered in the
liver  (Fig. 4C). In addition, basal levels of Gpx2 expres-
sion were found to be 152-fold higher in the pancreas
relative to the liver. In contrast, basal levels of Cat mRNA
were approximately 600-fold higher in the liver as com-
pared  to the pancreas. While Cat mRNA levels failed to be
induced  by PFOA treatment in the pancreas, PFOA exposure
increased expression by 1.3-fold in the liver (Fig. 4D). Basal
mRNA  levels of NAD(P)H:quinone oxidoreductase 1 (Nqo1)
were  approximately 36-fold higher in the pancreas; how-
ever,  comparable levels of mRNA induction (1.6–2-fold)
were observed in both the pancreas and liver following 2.5
and  5.0 mg/kg BW/day PFOA treatment (Fig. 4E). Cerulein
treatment led to significant induction of the antioxidant
response genes Sod1, Sod2, Gpx2 and Nqo1 mRNA in the
pancreas, but not the liver, further illustrating its pancreas-
selective effects (Fig. 4).
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mean  ± S.D. Results are expressed relative to control levels in the pancrea
4. Discussion
PFOA has been detected in air and wildlife worldwide,
with measurable PFOA levels found in more than 98%
of  the US general population [3]. Recent epidemiologic
studies have shown that increased levels of PFOA are sig-
nificantly correlated with development of diabetes in bothing normalization to -actin as described in Section 2. The mRNA levels
e calculated from groups (n = 4 mice/group). Data are expressed as group
 were set to 1.0. *Significantly different from control (p < 0.05).
occupationally exposed workers [9] and adult women that
were  exposed in utero to PFOA [8]. Further, a weak link was
found  between PFOA levels and development of pancreatic
cancer [10]. While PFOA has been shown to accumulate in
the  serum, kidney and liver of treated rodents [1,11], levels
of  PFOA have not been previously measured in the pan-
creas.  We  show in this study that a 7 day exposure of mice
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o PFOA leads to significant accumulation of PFOA in the
erum,  liver and also the pancreas (Table 2).
The function of the acinar cell, the major cell type of the
xocrine pancreas, is to synthesize, store and secrete diges-
ive  enzymes, which are activated following their transport
o  the lumen of the small intestine. Pancreatitis results
rom the inappropriate intracellular activation of pancre-
tic  enzymes, leading to autodigestion of the organ and
n  inflammatory response. A common experimental model
f  pancreatitis used in mice involves stimulation of aci-
ar  cells with the secretagogue cholecystokinin (CCK) or
ts  synthetic analog cerulein [29,33]. Elevated serum amy-
ase  and lipase levels are used as a diagnostic indicator
or acute pancreatitis in humans, and are observed after
cute  cerulein administration in rodents. While treatment
ith physiological concentrations of CCK stimulates pan-
reatic  enzyme secretion, application of supraphysiological
oncentrations can cause inhibition of secretion [34]. With
espect  to the ability of PFOA to alter CCK, a study of PFOA
roduction workers found no correlation between serum
FOA  and CCK levels, suggesting that PFOA exposure does
ot  modulate CCK levels [35].
In our study, serum amylase and lipase levels were
ignificantly elevated only in the 2.5 mg/kg BW/day PFOA
reatment group (Fig. 2). It has previously been demon-
trated that serum levels of amylase return to normal
ithin 24 h after cerulein treatment [36]. Since amylase
nd lipase levels were assessed 24 h after the last dose in
ur  study, the levels may  have been elevated at earlier time
oints  and may  provide an explanation for the lack of sig-
ificant  elevation of these levels in the cerulein treatment
roup and perhaps the high dose PFOA group.
Alternatively, ROS have been shown to both stimulate
mylase release in mouse pancreatic acinar cells [37] as
ell  as cause inhibition of CCK-stimulated amylase release
n  vitro [38,39]. At low doses, PFOA-mediated ROS pro-
uction may  thus act to stimulate enzyme secretion while
t  a higher dose (5.0 mg/kg BW/day) PFOA-stimulated ROS
roduction  may  inhibit secretion. This may  be due to the
ncreased lipid peroxidation products observed in the high
ose  group, which have been shown to trigger loss of
a2+ homeostasis, critical for stimulus-secretion coupling
reviewed in [40]). A definitive answer of whether PFOA
timulates acinar cell enzyme secretion and/or pancreati-
is  and the mechanism through which this occurs requires
dditional experimentation.
Chronic  oxidative stress has long been associated with
isease pathologies observed in atherosclerosis, aging and
ancer  [22]. Previous studies have shown that PFOA causes
ncreased ROS generation and oxidative DNA damage in
epG2  cells [23,25] and increased malondialdehyde (MDA)
evels  in cultured tilapia hepatocytes [32]. Consistent with
hese  results, we observed a dose-dependent increase in
he  lipid peroxidation product 8-iso-PGF2 in the pan-
reas following exposure to PFOA for 7 days, similar to the
nduction  seen with cerulein, an agent known to induce
ancreatic inflammation and oxidative stress (Fig. 3A).
lthough PFOA levels in the liver were found to be 18–30-
old  higher than in the pancreas (Table 2), the pancreas
ustained significantly increased fold-changes in 8-iso-
GF2 in all treatment groups when compared to the liver,Reports 1 (2014) 513–521 519
suggesting that the pancreas may  be more susceptible to
oxidative  damage at lower levels of PFOA exposure. ROS
can  be detoxified by cellular enzymes, such as Sod, Gpx, Cat,
and  Nqo1 which are commonly induced as a consequence
of oxidative stress [22]. While PFOA stimulated the induc-
tion  of Sod1, Sod2 and Nqo1 mRNA in both pancreas and
liver,  Gpx2 expression was induced only in the pancreas
and Cat expression was  induced only in the liver (Fig. 4).
In  addition, we  observed differing levels of basal expres-
sion  of antioxidant genes in the liver and pancreas. While
the  pancreas expresses greater levels of Gpx2 and Nqo1,
the  liver exhibited significantly higher levels (600-fold) of
Cat  mRNA. While mRNA levels do not always correlate with
protein  or activity levels, the lower Cat mRNA expression in
the  pancreas we observed is consistent with previous stud-
ies  demonstrating that catalase activity in the pancreas is
only  5% of the activity in the liver [41]. These differences
in the expression of ROS detoxification enzymes, in partic-
ular  Cat, may  act to mitigate the potential oxidative stress
elicited by higher PFOA concentrations in the liver relative
to  the pancreas.
5.  Conclusion
We  show here that exposure of mice to PFOA for 7 days
triggers oxidative stress in the pancreas, which is associ-
ated  with altered pancreatic enzyme secretion, focal ductal
hyperplasia and inflammation. The conditions of pancre-
atitis,  diabetes, and obesity, as well as other exposures
which cause oxidative stress, such as smoking and alco-
hol  consumption, are risk factors for the development of
pancreatic cancer [42]. Long-term PFOA exposure has been
shown  to induce pancreatic acinar cell tumors in rats [1].
In  addition, targeting expression of oncogenic KRasG12V
to adult mouse acinar cells, in combination with mild
pancreatitis, led to development of pancreatic ductal ade-
nocarcinoma [19,20], firmly establishing the acinar cell as
a  cell of origin for PDAC [43,44]. As exposure to PFOA has
been  shown to increase ROS in vitro and we have shown
here  that PFOA causes oxidative stress in the pancreas,
exposure to PFOA may  stimulate an inflammatory response
which  may  contribute to the development or progression
of  pancreatic cancer [45]. Given that measurable levels
of  PFOA are found in the general population, additional
studies targeted at investigating the mechanism of PFOA-
induced pancreatic toxicity will thus provide information
that can be used to better characterize the potential human
health  risks associated with chronic exposure to PFOA.
Transparency document
The  Transparency document associated with this article
can be found in the online version.
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